Egle Therapeutics is a biotechnology company focused on developing immunotherapies for oncology and autoimmune diseases.
Egle Therapeutics has raised $9.4M in total funding. The most recent round was Grant. The last funding was announced in March 2026.
Egle Therapeutics's investors include Bpifrance, EQT Life Sciences, European Commission, France 2030, Bioqube Ventures.
Egle Therapeutics is headquartered in Paris, France.
Egle Therapeutics is a biotechnology company focused on developing immunotherapies for oncology and autoimmune diseases.
Egle Therapeutics is at the Grant stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Egle Therapeutics — Funding & Investors." VCBacked, March 2, 2026, https://www.vcbacked.co/company/egle-therapeutics. Accessed September 29, 2026.
VCBacked. (2026). Egle Therapeutics — Funding & Investors. Retrieved September 29, 2026, from https://www.vcbacked.co/company/egle-therapeutics
{{cite web |title=Egle Therapeutics — Funding & Investors |url=https://www.vcbacked.co/company/egle-therapeutics |website=VCBacked |access-date=September 29, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated